BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
BCLI$1.14-7.3%Stored close · as of Jul 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · Additional · · · · · · · Total | |||||||||||||||||
| · · Common stock · · paid-in · · Treasury · · Accumulated · · stockholders’ | |||||||||||||||||
| · Number (**) · Amount · capital · stocks · deficit · equity | |||||||||||||||||
| Balance as of January 1, 2023 | 2,446,272 | | $12 | | $194,910 | | | (116) | | $(197,821) | | $(3,015) | |||||
| | | | | | | | | | | | | | | | | | |
| Stock-based compensation related to stock and options granted to directors and employees | 42,022 | | | * | | | 1,490 | | | — | | | — | | | 1,490 | |
| Issuance of shares in at-the-market (ATM) offering (Note 8) | | 1,274,050 | | | 1 | | | 11,880 | | | — | | | — | | | 11,881 |
| Issuance of shares for private placement (Note 8) | | 270,270 | | | * | | | 1,978 | | | — | | | — | | | 1,978 |
| Net loss | — | | | — | | | — | | | — | | | (17,192) | | | (17,192) | |
| | | | | | | | | | | | | | | | | | |
| Balance as of December 31, 2023 | 4,032,614 | | | 13 | | | 210,258 | | | (116) | | | (215,013) | | | (4,858) | |
- Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · Additional · · · · · · · Total | |||||||||||||||||
| · · Common stock · · paid-in · · Treasury · · Accumulated · · stockholders’ | |||||||||||||||||
| · Number (**) · Amount · capital · stocks · deficit · equity | |||||||||||||||||
| Balance as of January 1, 2024 | 4,032,614 | | $13 | | $210,258 | | | (116) | | $(215,013) | | $(4,858) | |||||
| | | | | | | | | | | | | | | | | | |
| Stock-based compensation related to stock granted to service providers | 9,893 | | | | 52 | | — | | — | | 52 | ||||||
| Stock-based compensation related to stock and options granted to directors and employees | 107,638 | | | * | | | 698 | | | — | | | — | | | 698 | |
| Issuance of shares in at-the-market (ATM) offering (Note 8) | | 1,250,876 | | | 1 | | | 4,322 | | | — | | | — | | | 4,323 |
| Issuance of shares for private placement (Note 8) | 740,741 | | | * | | | 3,644 | | | — | | | — | | | 3,644 | |
| Net loss | — | | | — | | | — | | | — | | | (11,623) | | | (11,623) | |
| | | | | | | | | | | | | | | | | | |
| Balance as of December 31, 2024 | 6,141,762 | | | 14 | | | 218,974 | | | (116) | | | (226,636) | | | (7,764) | |
- Represents an amount less than $1.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.